Header Logo

MICHAEL CURRAN

TitleAssistant Professor
InstitutionMD Anderson
DepartmentImmunology
Address7455 Fannin St
Houston TX 77054-1901
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. DeAzevedo R, Steiner M, Turner BX, Liu A, Newton S, Schmidt J, Fleming R, Tolentino A, Kaseb AO, Curran MA. Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma. J Immunother Cancer. 2024 Oct 30; 12(10). PMID: 39477243; PMCID: PMC11529525.
      Citations:    Fields:    Translation:HumansAnimalsCells
    2. Du R, Zhang J, Lukas RV, Tripathi S, Ahrendsen JT, Curran MA, Dmello C, Zhang P, Stupp R, Rao G, Heimberger AB. Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy? Neuro Oncol. 2024 Oct 19. PMID: 39427326.
      Citations:    Fields:    
    3. LaPelusa M, Chamseddine S, Tran Cao HS, Xiao L, Hasanov E, Bhosale P, Amin HM, Mohamed YI, Gok Yavuz B, Sakr Y, Xu L, Hu I, Lee SS, Sakamuri D, Jindal S, Nguyen V, Curran MA, Sun R, Rashid A, Duda DG, Sharma P, Qayyum A, Kaseb AO, LaPelusa M, Chamseddine S, Tran Cao HS, Xiao L, Hasanov E, Bhosale P, Amin HM, Mohamed YI, Gok Yavuz B, Sakr Y, Xu L, Hu I, Lee SS, Sakamuri D, Jindal S, Nguyen V, Curran MA, Sun R, Rashid A, Duda DG, Sharma P, Qayyum A, Kaseb AO. Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma. Oncology. 2024 Oct 18; 1-8. PMID: 39427654.
      Citations:    Fields:    
    4. Deng Y, Zhao Z, Sheldon M, Zhao Y, Teng H, Martinez C, Zhang J, Lin C, Sun Y, Yao F, Curran MA, Zhu H, Ma L. LIFR regulates cholesterol-driven bidirectional hepatocyte-neutrophil cross-talk to promote liver regeneration. Nat Metab. 2024 Sep; 6(9):1756-1774. PMID: 39147934; PMCID: PMC11498095.
      Citations:    Fields:    Translation:AnimalsCells
    5. Yim SY, Lee SH, Baek SW, Sohn B, Jeong YS, Kang SH, Park K, Park H, Lee SS, Kaseb AO, Park YN, Leem SH, Curran MA, Kim JH, Lee JS, Lee SH, Baek SW, Sohn B, Jeong YS, Park K, Park H, Lee SS, Kaseb AO, Leem SH, Curran MA, Lee JS. Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial. Clin Mol Hepatol. 2024 Oct; 30(4):807-823. PMID: 39038962; PMCID: PMC11540371.
      Citations: 1     Fields:    
    6. Najem H, Lea ST, Tripathi S, Hurley L, Chen CH, William I, Sooreshjani M, Bowie M, Hartley G, Dussold C, Pacheco S, Dmello C, Lee-Chang C, McCortney K, Steffens A, Walshon J, Ott M, Wei J, Marisetty A, Balyasnikova I, Stupp R, Lukas RV, Hu J, James CD, Horbinski CM, Lesniak MS, Ashley DM, Priebe W, Platanias LC, Curran MA, Heimberger AB. STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma. J Clin Invest. 2024 Jun 17; 134(12). PMID: 38941297; PMCID: PMC11178548.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    7. Boda AR, Liu AJ, Castro-Pando S, Whitfield BT, Molldrem JJ, Al-Atrash G, Di Francesco ME, Jones P, Ager CR, Curran MA. Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia. Cancer Res Commun. 2024 Mar 25; 4(3):911-918. PMID: 38477596; PMCID: PMC10962316.
      Citations: 1     Fields:    Translation:HumansCells
    8. Liu A, Gammon ST, Pisaneschi F, Boda A, Ager CR, Piwnica-Worms D, Hong DS, Curran MA. Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration. JCI Insight. 2024 Jan 09; 9(1). PMID: 37988164; PMCID: PMC10906452.
      Citations:    Fields:    Translation:HumansCells
    9. Fan Y, Song S, Li Y, Dhar SS, Jin J, Yoshimura K, Yao X, Wang R, Scott AW, Pizzi MP, Wu J, Ma L, Calin GA, Hanash S, Wang L, Curran M, Ajani JA. Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T-cell Immunity in Gastric Cancer Peritoneal Metastases. Cancer Res. 2023 11 15; 83(22):3726-3738. PMID: 37738407; PMCID: PMC10843008.
      Citations:    Fields:    Translation:AnimalsCells
    10. Koller P, Baran N, Harutyunyan K, Cavazos A, Mallampati S, Chin RL, Jiang Z, Sun X, Lee HH, Hsu JL, Williams P, Huang X, Curran MA, Hung MC, Konopleva M. PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity. J Immunother Cancer. 2023 10; 11(10). PMID: 37793852; PMCID: PMC10551962.
      Citations:    Fields:    Translation:HumansAnimals
    11. Chen CH, Chin RL, Hartley GP, Lea ST, Engel BJ, Hsieh CE, Prasad R, Roszik J, Shingu T, Lizee GA, Heimberger AB, Millward SW, Hu J, Hong DS, Curran MA. Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease. Neuro Oncol. 2023 08 03; 25(8):1415-1427. PMID: 36705543; PMCID: PMC10398813.
      Citations:    Fields:    Translation:HumansAnimalsCells
    12. Zhang Y, Zhao Z, Huang LA, Liu Y, Yao J, Sun C, Li Y, Zhang Z, Ye Y, Yuan F, Nguyen TK, Garlapati NR, Wu A, Egranov SD, Caudle AS, Sahin AA, Lim B, Beretta L, Calin GA, Yu D, Hung MC, Curran MA, Rezvani K, Gan B, Tan Z, Han L, Lin C, Yang L. Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metab. 2023 08 08; 35(8):1457-1473.e13. PMID: 37329887; PMCID: PMC10712687.
      Citations: 2     Fields:    Translation:AnimalsCells
    13. Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin JJ, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng XD, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, Wang L. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023 Jun; 29(6):1550-1562. PMID: 37248301; PMCID: PMC11421770.
      Citations: 26     Fields:    Translation:HumansCells
    14. Patel SA, Nilsson MB, Yang Y, Le X, Tran HT, Elamin YY, Yu X, Zhang F, Poteete A, Ren X, Shen L, Wang J, Moghaddam SJ, Cascone T, Curran M, Gibbons DL, Heymach JV. IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clin Cancer Res. 2023 04 03; 29(7):1292-1304. PMID: 36595561; PMCID: PMC10290888.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    15. Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Gr?nman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. JCI Insight. 2023 Feb 22; 8(4). PMID: 36810255; PMCID: PMC9990753.
      Citations: 1     Fields:    Translation:HumansCells
    16. Sun C, Ye Y, Tan Z, Liu Y, Li Y, Hu W, Liang K, Egranov SD, Huang LA, Zhang Z, Zhang Y, Yao J, Nguyen TK, Zhao Z, Wu A, Marks JR, Caudle AS, Sahin AA, Gao J, Gammon ST, Piwnica-Worms D, Hu J, Chiao PJ, Yu D, Hung MC, Curran MA, Calin GA, Ying H, Han L, Lin C, Yang L. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Sci Adv. 2023 02 03; 9(5):eadd6995. PMID: 36724291; PMCID: PMC9891701.
      Citations: 5     Fields:    Translation:HumansCells
    17. Son J, Hsieh RC, Lin HY, Krause KJ, Yuan Y, Biter AB, Welsh J, Curran MA, Hong DS. Inhibition of the CD47-SIRPa axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Front Immunol. 2022; 13:1027235. PMID: 36439116; PMCID: PMC9691650.
      Citations: 1     Fields:    Translation:HumansCells
    18. Zhang Y, Sun C, Li Y, Qin J, Amancherla K, Jing Y, Hu Q, Liang K, Zhang Z, Ye Y, Huang LA, Nguyen TK, Egranov SD, Zhao Z, Wu A, Xi Y, Yao J, Hung MC, Calin GA, Cheng J, Lim B, Lehmann LH, Salem JE, Johnson DB, Curran MA, Yu D, Han L, Darabi R, Yang L, Moslehi JJ, Lin C. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med. 2022 11 02; 14(669):eabo1981. PMID: 36322628; PMCID: PMC9809130.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    19. Tripathi S, Najem H, Mahajan AS, Zhang P, Low JT, Stegh AH, Curran MA, Ashley DM, James CD, Heimberger AB. cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma. F1000Res. 2022; 11:1010. PMID: 36324813; PMCID: PMC9597127.
      Citations:    Fields:    Translation:Humans
    20. Hsieh RC, Krishnan S, Wu RC, Boda AR, Liu A, Winkler M, Hsu WH, Lin SH, Hung MC, Chan LC, Bhanu KR, Srinivasamani A, De Azevedo RA, Chou YC, DePinho RA, Gubin M, Vilar E, Chen CH, Slay R, Jayaprakash P, Hegde SM, Hartley G, Lea ST, Prasad R, Morrow B, Couillault CA, Steiner M, Wang CC, Venkatesulu BP, Taniguchi C, Kim YSB, Chen J, Rudqvist NP, Curran MA. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol. 2022 06 10; 7(72):eabl9330. PMID: 35687697; PMCID: PMC9373855.
      Citations:    Fields:    Translation:HumansAnimalsCells
    21. Grindel BJ, Engel BJ, Ong JN, Srinivasamani A, Liang X, Zacharias NM, Bast RC, Curran MA, Takahashi TT, Roberts RW, Millward SW. Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display. ACS Chem Biol. 2022 06 17; 17(6):1543-1555. PMID: 35611948; PMCID: PMC10691555.
      Citations:    Fields:    Translation:Animals
    22. Wei J, Song R, Sabbagh A, Marisetty A, Shukla N, Fang D, Najem H, Ott M, Long J, Zhai L, Lesniak MS, James CD, Platanias L, Curran M, Heimberger AB. Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system. Oncoimmunology. 2022; 11(1):2062827. PMID: 35433114; PMCID: PMC9009928.
      Citations:    Fields:    Translation:Humans
    23. Chen CH, Curran MA. Method of long-term, recurrent, intracerebroventricular infusion of cellular therapy in mice. J Neurosci Methods. 2022 04 01; 371:109529. PMID: 35183615; PMCID: PMC8917793.
      Citations:    Fields:    Translation:Animals
    24. Sousa LG, Rajapakshe K, Rodriguez Canales J, Chin RL, Feng L, Wang Q, Barrese TZ, Massarelli E, Johnson FM, Ferrarotto R, Wistuba I, Coarfa C, Lee J, Wang J, Melief CJM, Curran MA, Glisson BS, William W. ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer. 2022 02; 10(2). PMID: 35193933; PMCID: PMC9066369.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    25. Jayaprakash P, Vignali PDA, Delgoffe GM, Curran MA. Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy. Annu Rev Med. 2022 01 27; 73:251-265. PMID: 34699264.
      Citations: 1     Fields:    Translation:HumansCells
    26. Gok Yavuz B, Hasanov E, Lee SS, Mohamed YI, Curran MA, Koay EJ, Cristini V, Kaseb AO. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1195-1207. PMID: 34595140; PMCID: PMC8478438.
      Citations: 3     
    27. Boudreau CE, Najem H, Ott M, Horbinski C, Fang D, DeRay CM, Levine JM, Curran MA, Heimberger AB. Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma. Clin Cancer Res. 2021 10 15; 27(20):5528-5535. PMID: 34433652; PMCID: PMC8989401.
      Citations: 2     Fields:    Translation:Animals
    28. Shen R, Postow MA, Adamow M, Arora A, Hannum M, Maher C, Wong P, Curran MA, Hollmann TJ, Jia L, Al-Ahmadie H, Keegan N, Funt SA, Iyer G, Rosenberg JE, Bajorin DF, Chapman PB, Shoushtari AN, Betof AS, Momtaz P, Merghoub T, Wolchok JD, Panageas KS, Callahan MK. LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Sci Transl Med. 2021 08 25; 13(608). PMID: 34433638; PMCID: PMC9254663.
      Citations: 13     Fields:    Translation:HumansCells
    29. Ager CR, Boda A, Rajapakshe K, Lea ST, Di Francesco ME, Jayaprakash P, Slay RB, Morrow B, Prasad R, Dean MA, Duffy CR, Coarfa C, Jones P, Curran MA. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. J Immunother Cancer. 2021 08; 9(8). PMID: 34341132; PMCID: PMC8330562.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    30. Sabbagh A, Beccaria K, Ling X, Marisetty A, Ott M, Caruso H, Barton E, Kong LY, Fang D, Latha K, Zhang DY, Wei J, DeGroot J, Curran MA, Rao G, Hu J, Carpentier A, Heimberger AB, Desseaux C, Bouchoux G, Canney M. Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. Clin Cancer Res. 2021 08 01; 27(15):4325-4337. PMID: 34031054; PMCID: PMC9012394.
      Citations: 10     Fields:    Translation:Animals
    31. Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov. 2021 06; 11(6):1368-1397. PMID: 33811048; PMCID: PMC8178168.
      Citations: 25     Fields:    Translation:Humans
    32. Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clin Cancer Res. 2021 06 01; 27(11):3050-3060. PMID: 33771853; PMCID: PMC8172466.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    33. de Azevedo RA, Shoshan E, Whang S, Markel G, Jaiswal AR, Liu A, Curran MA, Bar-Eli M, Travassos LR. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. Oncoimmunology. 2020 12 06; 9(1):1846915. PMID: 33344042; PMCID: PMC7733907.
      Citations: 10     Fields:    Translation:Humans
    34. Jaiswal AR, Liu AJ, Pudakalakatti S, Dutta P, Jayaprakash P, Bartkowiak T, Ager CR, Wang ZQ, Reuben A, Cooper ZA, Ivan C, Ju Z, Nwajei F, Wang J, Davies MA, Davis RE, Wargo JA, Bhattacharya PK, Hong DS, Curran MA. Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunol Res. 2020 11; 8(11):1365-1380. PMID: 32917656; PMCID: PMC7642111.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    35. Ott M, Tomaszowski KH, Marisetty A, Kong LY, Wei J, Duna M, Blumberg K, Ji X, Jacobs C, Fuller GN, Langford LA, Huse JT, Long JP, Hu J, Li S, Weinberg JS, Prabhu SS, Sawaya R, Ferguson S, Rao G, Lang FF, Curran MA, Heimberger AB. Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight. 2020 09 03; 5(17). PMID: 32721947; PMCID: PMC7526457.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    36. Rao G, Latha K, Ott M, Sabbagh A, Marisetty A, Ling X, Zamler D, Doucette TA, Yang Y, Kong LY, Wei J, Fuller GN, Benavides F, Sonabend AM, Long J, Li S, Curran M, Heimberger AB. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clin Cancer Res. 2020 09 01; 26(17):4699-4712. PMID: 32554515; PMCID: PMC7483850.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    37. Kamalinia G, Engel BJ, Srinivasamani A, Grindel BJ, Ong JN, Curran MA, Takahashi TT, Millward SW, Roberts RW. mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1). ACS Chem Biol. 2020 06 19; 15(6):1630-1641. PMID: 32352272; PMCID: PMC7416570.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    38. Wei J, Chen P, Gupta P, Ott M, Zamler D, Kassab C, Bhat KP, Curran MA, de Groot JF, Heimberger AB. Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2020 02 20; 22(2):180-194. PMID: 31679017; PMCID: PMC7442334.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    39. Liu A, Curran MA. Tumor hypermetabolism confers resistance to immunotherapy. Semin Cancer Biol. 2020 10; 65:155-163. PMID: 31982512.
      Citations: 4     Fields:    Translation:HumansCells
    40. Reilley MJ, Morrow B, Ager CR, Liu A, Hong DS, Curran MA. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. J Immunother Cancer. 2019 11 26; 7(1):323. PMID: 31771649; PMCID: PMC6880482.
      Citations: 23     Fields:    Translation:AnimalsCells
    41. Dorta-Estremera S, Hegde VL, Slay RB, Sun R, Yanamandra AV, Nicholas C, Nookala S, Sierra G, Curran MA, Sastry KJ. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer. J Immunother Cancer. 2019 09 18; 7(1):252. PMID: 31533840; PMCID: PMC6749627.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    42. Ager CR, Zhang H, Wei Z, Jones P, Curran MA, Di Francesco ME. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. Bioorg Med Chem Lett. 2019 10 15; 29(20):126640. PMID: 31500996; PMCID: PMC6993876.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    43. Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, Park PK, Liu J, Coarfa C, Donepudi SR, Putluri V, Putluri N, Sreekumar A, Ambati CR, Hawke DH, Marks JR, Gunaratne PH, Caudle AS, Sahin AA, Hortobagyi GN, Meric-Bernstam F, Chen L, Yu D, Hung MC, Curran MA, Han L, Lin C, Yang L. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019 07; 20(7):835-851. PMID: 31160797; PMCID: PMC6619502.
      Citations: 113     Fields:    Translation:HumansAnimalsCells
    44. Kapp K, Volz B, Curran MA, Oswald D, Wittig B, Schmidt M. EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy. J Immunother Cancer. 2019 01 08; 7(1):5. PMID: 30621769; PMCID: PMC6323716.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    45. Curran MA, Glisson BS. New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation. Annu Rev Med. 2019 01 27; 70:409-424. PMID: 30379596.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    46. Zhou L, Husted H, Moore T, Lu M, Deng D, Liu Y, Ramachandran V, Arumugam T, Niehrs C, Wang H, Chiao P, Ling J, Curran MA, Maitra A, Hung MC, Lee JE, Logsdon CD, Hwang RF. Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. Sci Transl Med. 2018 10 24; 10(464). PMID: 30355799; PMCID: PMC6752716.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    47. Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, Ager C, Nicholas C, Jaiswal AR, Sun Y, Shah K, Balasubramanyam S, Li N, Wang G, Ning J, Zal A, Zal T, Curran MA. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest. 2018 11 01; 128(11):5137-5149. PMID: 30188869; PMCID: PMC6205399.
      Citations: 125     Fields:    Translation:AnimalsCells
    48. Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW, Gr?nman RA. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. JCI Insight. 2018 08 23; 3(16). PMID: 30135316; PMCID: PMC6141174.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    49. Dorta-Estremera S, Chin RL, Sierra G, Nicholas C, Yanamandra AV, Nookala SMK, Yang G, Singh S, Curran MA, Sastry KJ. Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers. Cancer Res. 2018 09 15; 78(18):5327-5339. PMID: 30054333; PMCID: PMC6524525.
      Citations: 10     Fields:    Translation:AnimalsCells
    50. Buchan SL, Fallatah M, Thirdborough SM, Taraban VY, Rogel A, Thomas LJ, Penfold CA, He LZ, Curran MA, Keler T, Al-Shamkhani A. PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity. Clin Cancer Res. 2018 05 15; 24(10):2383-2394. PMID: 29514845; PMCID: PMC5959006.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    51. Bartkowiak T, Jaiswal AR, Ager CR, Chin R, Chen CH, Budhani P, Ai M, Reilley MJ, Sebastian MM, Hong DS, Curran MA. Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. Clin Cancer Res. 2018 03 01; 24(5):1138-1151. PMID: 29301830; PMCID: PMC6752715.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    52. Curran MA. Preclinical Data Supporting Antitumor Activity of PD-1 Blockade. Cancer J. 2018 Jan/Feb; 24(1):2-6. PMID: 29360721.
      Citations: 2     Fields:    Translation:HumansAnimals
    53. Singh M, Vianden C, Cantwell MJ, Dai Z, Xiao Z, Sharma M, Khong H, Jaiswal AR, Faak F, Hailemichael Y, Janssen LME, Bharadwaj U, Curran MA, Diab A, Bassett RL, Tweardy DJ, Hwu P, Overwijk WW. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017 11 13; 8(1):1447. PMID: 29129918; PMCID: PMC5682289.
      Citations: 37     Fields:    Translation:AnimalsCells
    54. Ager CR, Reilley MJ, Nicholas C, Bartkowiak T, Jaiswal AR, Curran MA. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. Cancer Immunol Res. 2017 08; 5(8):676-684. PMID: 28674082; PMCID: PMC5547907.
      Citations: 68     Fields:    Translation:HumansAnimalsCells
    55. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396. PMID: 27649551; PMCID: PMC5355002.
      Citations: 137     Fields:    Translation:HumansCellsCTClinical Trials
    56. Chouaib S, Noman MZ, Kosmatopoulos K, Curran MA. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene. 2017 01 26; 36(4):439-445. PMID: 27345407; PMCID: PMC5937267.
      Citations:    
    57. Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K, Ghia P. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 2016 05; 101(5):531-40. PMID: 27132279; PMCID: PMC5004369.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    58. Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016; 1(2). PMID: 26973881; PMCID: PMC4784261.
      Citations: 194     Fields:    
    59. Curran MA, Fox BA, Redmond WL. Editorial: Advances in Combination Tumor Immunotherapy. Front Oncol. 2015; 5:198. PMID: 26442210; PMCID: PMC4585267.
      Citations:    
    60. Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, Allison JP, Sastry KJ, Curran MA. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A. 2015 Sep 22; 112(38):E5290-9. PMID: 26351680; PMCID: PMC4586868.
      Citations: 34     Fields:    Translation:AnimalsCells
    61. Bartkowiak T, Curran MA. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol. 2015; 5:117. PMID: 26106583; PMCID: PMC4459101.
      Citations: 93     
    62. Ai M, Curran MA. Immune checkpoint combinations from mouse to man. Cancer Immunol Immunother. 2015 Jul; 64(7):885-92. PMID: 25555570; PMCID: PMC11028659.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    63. Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med. 2013 Apr 08; 210(4):743-55. PMID: 23547098; PMCID: PMC3620352.
      Citations: 76     Fields:    Translation:AnimalsCells
    64. Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-?B signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics. 2012 Oct; 9(4):827-43. PMID: 22996231; PMCID: PMC3480576.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    65. Jenq RR, Curran MA, Goldberg GL, Liu C, Allison JP, van den Brink MR. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. PLoS One. 2012; 7(4):e35222. PMID: 22493742; PMCID: PMC3320876.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    66. Curran MA, Callahan MK, Subudhi SK, Allison JP. Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". Immunobiology. 2012 Jun; 217(6):590-2. PMID: 22459268.
      Citations: 3     Fields:    Translation:Humans
    67. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One. 2011 Apr 29; 6(4):e19499. PMID: 21559358; PMCID: PMC3085474.
      Citations: 99     Fields:    Translation:AnimalsCells
    68. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010 Mar 02; 107(9):4275-80. PMID: 20160101; PMCID: PMC2840093.
      Citations: 772     Fields:    Translation:AnimalsCells
    69. Curran MA, Allison JP. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res. 2009 Oct 01; 69(19):7747-55. PMID: 19738077; PMCID: PMC2756314.
      Citations: 72     Fields:    Translation:AnimalsCells
    70. Duan F, Lin Y, Liu C, Engelhorn ME, Cohen AD, Curran M, Sakaguchi S, Merghoub T, Terzulli S, Wolchok JD, Houghton AN. Immune rejection of mouse tumors expressing mutated self. Cancer Res. 2009 Apr 15; 69(8):3545-53. PMID: 19351857; PMCID: PMC2767208.
      Citations: 7     Fields:    Translation:AnimalsCells
    71. Fenjves ES, Ochoa MS, Cechin S, Gay-Rabinstein C, Ichii H, Mendez A, Ricordi C, Curran MA, P?rez-Alvarez I. Protection of human pancreatic islets using a lentiviral vector expressing two genes: cFLIP and GFP. Cell Transplant. 2008; 17(7):793-802. PMID: 19044206.
      Citations: 4     Fields:    Translation:HumansCells
    72. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006 Jul; 116(7):1935-45. PMID: 16778987; PMCID: PMC1479425.
      Citations: 337     Fields:    Translation:AnimalsCells
    73. Shai E, Palmon A, Panet A, Marmary Y, Sherman Y, Curran MA, Galun E, Condiotti R. Prolonged transgene expression in murine salivary glands following non-primate lentiviral vector transduction. Mol Ther. 2005 Jul; 12(1):137-43. PMID: 15963929.
      Citations: 10     Fields:    Translation:AnimalsCells
    74. Condiotti R, Curran MA, Nolan GP, Giladi H, Ketzinel-Gilad M, Gross E, Galun E. Prolonged liver-specific transgene expression by a non-primate lentiviral vector. Biochem Biophys Res Commun. 2004 Jul 30; 320(3):998-1006. PMID: 15240147.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    75. Wolkowicz R, Nolan GP, Curran MA. Lentiviral vectors for the delivery of DNA into mammalian cells. Methods Mol Biol. 2004; 246:391-411. PMID: 14970606.
      Citations: 8     Fields:    Translation:HumansCells
    76. Fenjves ES, Ochoa MS, Gay-Rabinstein C, Ricordi C, Curran MA. Retrovirally transferred genes inhibit apoptosis in an insulin-secreting cell line: implications for islet transplantation. Cell Transplant. 2004; 13(5):489-96. PMID: 15565861.
      Citations:    Fields:    Translation:AnimalsCells
    77. Price MA, Case SS, Carbonaro DA, Yu XJ, Petersen D, Sabo KM, Curran MA, Engel BC, Margarian H, Abkowitz JL, Nolan GP, Kohn DB, Crooks GM. Expression from second-generation feline immunodeficiency virus vectors is impaired in human hematopoietic cells. Mol Ther. 2002 Nov; 6(5):645-52. PMID: 12409263.
      Citations: 11     Fields:    Translation:HumansCells
    78. Curran MA, Ochoa MS, Molano RD, Pileggi A, Inverardi L, Kenyon NS, Nolan GP, Ricordi C, Fenjves ES. Efficient transduction of pancreatic islets by feline immunodeficiency virus vectors1. Transplantation. 2002 Aug 15; 74(3):299-306. PMID: 12177606.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    79. Curran MA, Nolan GP. Recombinant feline immunodeficiency virus vectors. Preparation and use. Methods Mol Med. 2002; 69:335-50. PMID: 11987787.
      Citations: 3     Fields:    Translation:HumansCells
    80. Curran MA, Nolan GP. Nonprimate lentiviral vectors. Curr Top Microbiol Immunol. 2002; 261:75-105. PMID: 11892254.
      Citations: 5     Fields:    Translation:AnimalsCells
    81. Curran MA, Kaiser SM, Achacoso PL, Nolan GP. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol Ther. 2000 Jan; 1(1):31-8. PMID: 10933909.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    82. Editorial. Frontiers in Oncology. 5.
    83. 4-1BB agonists. Frontiers in Oncology. 5.
    84. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 101:531-540.
    CURRAN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (370)
    Explore
    _
    Co-Authors (113)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _